DB
MREO

Dmitry Balyasny’s Mereo BioPharma MREO Stock Holding History

Dmitry Balyasny’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,280,275
Closed -$533K – 3281
2025
Q4 		$533K Buy
+1,280,275
New +$2.44M ﹤0.01% 2499
2022
Q4 		– Sell
-19,211
Closed -$17K – 3055
2022
Q3 		$17K Buy
+19,211
New +$23.5K ﹤0.01% 2597

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Dmitry Balyasny's MREO Position: Q1 2026 in Review

Dmitry Balyasny sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 1,280,275 shares — an estimated $533K sold.

Dmitry Balyasny first reported a position in MREO in Q3 2022 and held it in 2 quarters. The position peaked at $533K in Q4 2025. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Dmitry Balyasny reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 1,280,275 Mereo BioPharma shares in Q1 2026, an estimated $533K.
  • Dmitry Balyasny first reported a position in Mereo BioPharma in Q3 2022 and held it in 2 quarters.
  • Dmitry Balyasny's Mereo BioPharma position peaked at $533K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.